CLINICAL_TRIALS
trial_result
· 2015-11-11
Clinical Trial Update: Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1 [Phase 3]
Summary
A Phase 3 trial comparing once-daily versus twice-daily dosing of nitisinone in Hereditary Tyrosinemia Type I has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Swedish Orphan Biovitrum | Conditions: Hereditary Tyrosinemia, Type I | Phase 3 | Status: COMPLETED